Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Medtronic
Moodys
Colorcon

Last Updated: May 20, 2022

RYZODEG 70/30 Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for RYZODEG 70/30

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A
Novo Nordisk A/S

See all RYZODEG 70/30 clinical trials

Recent Litigation for RYZODEG 70/30

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novo Nordisk Inc. v. Alvogen, Inc.2022-03-03
NOVO NORDISK INC. v. SANDOZ INC.2020-06-04
Novo Nordisk Inc. v. Sandoz Inc.2020-06-03

See all RYZODEG 70/30 litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RYZODEG 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RYZODEG 70/30 Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 See Plans and Pricing 2016-06-20 Company disclosures
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 See Plans and Pricing 2021-01-05 Company disclosures
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 See Plans and Pricing 2023-08-05 Company disclosures
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 See Plans and Pricing 2024-10-21 Company disclosures
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 See Plans and Pricing 2021-01-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for RYZODEG 70/30 Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for RYZODEG 70/30

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122013000062 Germany See Plans and Pricing PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
92226 Luxembourg See Plans and Pricing PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121
300596 Netherlands See Plans and Pricing PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
92213 Luxembourg See Plans and Pricing PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001-4-5-7-8-9-12-13-15 TRESIBA 20130123
138 5015-2013 Slovakia See Plans and Pricing PRODUCT NAME: INZULIN DEGLUDEK; REGISTRATION NO/DATE: EU/1/12/807/001 - EU/1/12/807/015 20130121
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
Express Scripts
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.